17 suspended. 17 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Suspended 17 |
| Phase 2 | 5 | Suspended 5 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-10 | 2026-11-05 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-10 | 2026-11-05 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors CD70-targeted CAR-T cells - Renal Cell Carcinoma (RCC), Lung Cancer | Phase 1 | Suspended | Chongqing Precision Biotech Co., Ltd | 90 | 2025-09-12 | 2026-09-11 |
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | Dwight Owen | 24 | 2024-12-31 | 2026-09-18 |
| Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) Pembrolizumab, Difluoromethylornithine - Non Small Cell Lung Cancer, Lung Cancer | Phase 1 / Phase 2 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2024-08-07 | 2026-03-06 |
| Biodistribution & Pharmacokinetic of Position Emission Tomography (PET) Radiopharmaceutical 18F C SNAT4 18F-C-SNAT4, Positron emission tomography (PET)/Computed tomography (CT) Scan - Cancer, Lung Cancer | Phase 1 | Suspended | Stanford University | 20 | 2024-03-07 | 2026-08-12 |
| A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 NPX267 - Metastatic Malignant Neoplasm | Phase 1 | Suspended | NextPoint Therapeutics, Inc. | 131 | 2023-07-21 | 2025-06-27 |
| The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors Fermented Wheat Germ Extract - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | University of California, Davis | 100 | 2023-06-02 | 2026-07-01 |
| A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment - Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer | Phase 1 / Phase 2 | Suspended | Cancer Research UK | 15 | 2021-10-15 | 2026-04-06 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations JSI-1187, Dabrafenib - Solid Tumors | Phase 1 | Suspended | JS InnoPharm, LLC | 71 | 2020-06-18 | 2025-09-03 |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2 - Solid Tumor | Phase 1 | Suspended | PACT Pharma, Inc. | 21 | 2019-07-03 | 2022-08-18 |
| A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC AMG 119 - Small Cell Lung Cancer | Phase 1 | Suspended | Amgen | 6 | 2018-09-10 | 2025-10-15 |
| Radio-Immuno-Modulation in Lung Cancer Patients with a living donor, Patients with a UCB donor - Lung Cancer | Phase 1 | Suspended | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 24 | 2018-04-20 | 2024-02-29 |
| Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment Oshadi D and Oshadi R - Mesothelioma | Phase 1 / Phase 2 | Suspended | Oshadi Drug Administration | 17 | 2016-12-01 | 2018-04-18 |
| A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel - Cancer | Phase 1 | Suspended | Human Genome Sciences Inc., a GSK Company | 54 | 2012-06-01 | 2012-11-01 |
Lung Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (8) · Neoplasms (5) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Prostatic Neoplasms (3) · Small Cell Lung Carcinoma (3) · Carcinoma, Transitional Cell (2) · Melanoma (2) · Mesothelioma (2) · Ovarian Neoplasms (2) · Thyroid Carcinoma, Anaplastic (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma (1)
Lung Diseases (17) · Neoplasms by Site (17) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (17) · Neoplasms (12) · Bronchial Neoplasms (11) · Carcinoma, Bronchogenic (11) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Lung Neoplasms (7) · Carcinoma (6) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5)
Carboplatin (3) · Cisplatin (3) · Etoposide (2) · Paclitaxel (2) · durvalumab (2) · pembrolizumab (2) · ALT-803 (1) · Avemar (1) · Azacitidine (1) · Biological Assay (1) · Biological Products (1) · Docetaxel (1) · Eflornithine (1) · Gemcitabine (1) · HhAntag691 (1)
National Cancer Institute (NCI) (2) · Amgen (1) · Cancer Research UK (1) · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (1) · Chongqing Precision Biotech Co., Ltd (1) · Dwight Owen (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Human Genome Sciences Inc., a GSK Company (1) · JS InnoPharm, LLC (1) · NextPoint Therapeutics, Inc. (1) · Oshadi Drug Administration (1) · PACT Pharma, Inc. (1) · Stanford University (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, Davis (1)
United States (13) · Canada (1) · China (1) · Israel (1) · United Kingdom (1)
David S Schrump, M.D. (2) · Andrei H Iagaru, MD (1) · Donglai Lv, MD (1) · Dwight H Owen, MD (1) · Fiona Blackhall, Prof (1) · Hovav Nehushtan, Prof. (1) · Jared Weiss, MD (1) · Jhanelle E. Gray, M.D. (1) · Joseph M Tuscano, MD (1) · Leena Gandhi, MD, PhD (1) · Razvan B Diaconescu, MD (1) · Taofeek Owonikoko, MD, PhD (1)
PMID 35537408, PMID 36356599, PMID 39897044
2019 (1), P30CA093373 (1)